Objective: To examine the effects of galantamine and donepezil on patient and caregiver sleep.
A lzheimer disease (AD) is a chronic progressive neurodegenerative disorder characterized by a loss of cognitive and functional abilities that often is accompanied by attentional and behavioral disturbances. [1] [2] [3] Many patients with AD develop sleep/wake cycle disturbances as well, which are associated with distress and depression. 4, 5 These interruptions in patient sleep have been shown to also affect the quality and quantity of caregiver sleep. 4, 5 Furthermore, these negative effects on caregivers may lead to earlier patient placement in nursing homes. 4 A marked decrease of cholinergic activity is believed to contribute to the cognitive decline in patients with AD. 6 Acetylcholinesterase inhibitors (AChEIs) block the enzymatic breakdown of acetylcholine, increasing the amount that is available for neuronal function. [7] [8] [9] Acetylcholinesterase inhibitors currently approved for the treatment of mild to moderate AD include galantamine, donepezil, and rivastigmine.
Sleep disturbances, in particular insomnia and abnormal dreaming, [10] [11] [12] have been associated with donepezil treatment 13, 14 but less so with galantamine treatment. 15, 16 While these results suggest that galantamine may offer some advantage in maintaining quality of sleep in patients with AD, no direct comparison of the effects of these two agents on sleep quality has been previously published. In this randomized, double-blind, parallel-group, multicenter, pilot study, we examined the effects of galantamine and donepezil on both patient and caregiver sleep patterns. Changes in patient global function and the adverse effects associated with each drug also were assessed to determine whether the doses chosen for each drug had similar risk-benefit ratios.
METHODS

Patients and Study Design
Sixty-three community-dwelling patients with mild to moderate AD were randomized to 8 mg of galantamine BID (n = 31) or 10 mg of donepezil HS (n = 32). Patients were required to be $60 years of age, to score between 10 and 24 on the Mini-Mental State Examination, and to reside with a responsible caregiver who agreed to participate and to monitor sleep and answer questionnaires for both the patient and self. Key exclusion criteria included presence of other neurodegenerative diseases contributing to dementia (including multiinfarct dementia or clinically active cerebrovascular disease), other medical conditions causing cognitive impairment, clinically significant co-existing medical conditions (psychiatric, cardiovascular, or active peptic ulcer disease; urinary outflow obstruction; hepatic, renal, pulmonary, metabolic, or endocrine disturbances), and the use of a muscarinic 1 agonist or an AChEI within 30 days prior to enrollment.
The study included a 2-week, single-blind, placebo runin; an 8-week, double-blind assessment; and a variable-length, double-blind extension that continued until all patients had completed the 8-week assessment phase. Because comparable doses of these drugs had not been established, the total daily doses with similar effects on efficacy measures in pivotal trials were chosen. 10, 13, 17 Patients received galantamine 4 mg twice a day (with placebo qhs) or donepezil 5 mg every night at bedtime (placebo bid) for the first 4 weeks, after which doses were increased to galantamine 8 mg twice a day or donepezil 10 mg every night at bedtime for the remainder of the study. Each dosing and titration regimen was within product labeling.
Sleep measurements were obtained at baseline (week-1), post-titration (week 4), and after reaching stable medication doses (week 7), whereas global functioning and quality of life measurements reflected baseline and efficacy phase endpoint (week 8). New or more frequent use of sedative hypnotics was permitted during the study only if sleep problems became persistent or troublesome.
Outcome Measures Sleep Variables
Objective measurements of sleep in both the patient and caregiver were obtained using an Actiwatch Ò (Mini Mitter Co, Inc; Bend, Oregon) accompanied by a sleep log. The Actiwatch Ò is a wrist actigraph with an accelerometer that records wrist movement. Studies comparing actigraphy to the gold standard of polysomnography have shown that sleep and wake variables can be determined from wrist movements. 18 Both patients and caregivers wore an Actiwatch for three 7-day periods (baseline, week 4, and week 7 [downloaded at week 5 and 8 visits]). Percent sleep (percentage of time in bed sleeping), number of wake bouts (number of times the individual woke up), and median wake bout duration (median length of wake periods throughout each night for each subject) were selected as the indices most likely to reflect the sleep fragmentation associated with insomnia and nightmares reported with donepezil use. Actigraph data were edited and scored at the J. Christian Gillin Laboratory of Sleep and Chronobiology at the University of California, San Diego using the Actiware Ò sleep and activity monitoring software program (version 3.3, Mini Mitter Co, Inc; Bend, Oregon). Scorers were blind to the patients' conditions. Sleep/wake data were then analyzed using previously validated methodology. 19 The Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire, was used to obtain subjective measures of sleep for the preceding 7 days (ie, the same period during which the actigraph was worn). 20 Data from questions helped gather information on quality and patterns of sleep, including sleep latency, sleep duration, sleep disturbances, habitual efficiency, sleep medication use, and daytime dysfunction. Total PSQI scores range from 0-21 with higher scores indicating more disturbed sleep. Scores of 5 or above suggest impaired sleep. Caregivers completed the PSQI about the patient and about themselves.
Global Function
The Clinician's Interview-Based Impression of Change Plus Family Input (CIBIC-Plus) 21 was used to assess dose equivalency in terms of efficacy for four areas of patient function: general functioning, cognition, behavior, and performance of daily living activities. Change from baseline was rated on a scale from 1, indicating the most improvement, to 7, indicating the most deterioration. 21 
Safety and Tolerability
Data regarding physical exams, vital signs, spontaneously reported adverse events (AEs), and concomitant medications were collected at every visit.
Statistical Analyses
All analyses were performed on the intent-to-treat population. Due to the time needed to reach steady state from the dose levels, no last observation carried forward analysis was performed. All tests of significance for within-and betweengroup differences were done at the a = 0.05 level of significance (significance with a = 0.10 for interaction effects). No adjustment for multiplicity was performed because this pilot study was designed to explore multiple endpoints.
Analysis of within-group change from baseline was assessed using paired t tests along with 95% confidence intervals of the mean.
In general, between-group comparisons of categorical data were performed with either the Fisher exact test or Cochran-Mantel-Haenszel tests, stratifying for center. Betweengroup differences (continuous data) in change from baseline scores were assessed with either ANCOVA models, where baseline scores served as covariates, or ANOVA models. The effects in these models were treatment group and center main effects and their interaction. In addition, Pearson correlation coefficients were computed between patients and caregivers for actigraphy and PSQI parameters.
Because this was a pilot study with a small number of subjects, and with a hypothesis-generating intent, an a priori decision was made to focus analyses on identifying patterns in the data rather than on inferential statistical testing. Although the study was not powered to detect statistical differences, statistical analyses were performed for exploratory purposes. Not surprisingly, very few comparisons reached statistical significance, although as expected, patterns emerged. Discussion will focus on these patterns.
RESULTS
The intent-to-treat population included 31 galantaminetreated patients and their caregivers and 32 donepezil-treated patients and their caregivers. There were no statistically significant differences between treatment groups in either patient or caregiver baseline characteristics (Table 1) . Twenty-six patients in the galantamine group and 28 patients in the donepezil 
Sleep Outcomes Actigraphy
Changes in mean percent sleep at week 5 and week 8 for patients in both groups were minimal; however, as seen in Figure 1A , values increased for the galantamine group and decreased for the donepezil group. The same pattern was also seen for caregivers ( Fig. 1B) . This pattern was not seen in number of wake bouts or in wake bout time for patients but was present for caregivers ( Table 2) .
Pittsburgh Sleep Quality Index
The mean baseline Pittsburgh Sleep Quality Index (PSQI) scores were normal (ie, below 5 for both groups of patients and their caregivers) ( Table 3 ). Mean PSQI scores for both patient groups decreased over time (indicating improved sleep). While patients in the galantamine group showed larger decreases than those in the donepezil group both at week 5 and at week 8, caregivers of patients receiving galantamine showed greater decreases only at week 8 (Table 3) . However, a small number of patients in each group scored above 5. In an analysis of those patients with normal versus impaired sleep at baseline (PSQI scores of ,5 versus $5), mean values tended to improve in those patients with initially impaired sleep in both treatment groups at week 5 (GAL, 22.75, n = 8; DON, 22.43, n = 7) and at week 8 (GAL, 22.33, n = 6; DON, 21.33, n = 6) and remained normal in those patients with initially normal sleep at week 5 (GAL, 20.33, n = 12; DON, 0.63, n = 16) and at week 8 (GAL, 20.64, n = 11; DON, 0.22, n = 9). Similar patterns were seen for caregivers with normal or impaired sleep at baseline.
Correlations between patient and caregiver PSQI score changes from baseline to week 5 were r = 0.373 for galantamine and r = 0.240 for donepezil. Correlations at week 8 were r = 0.274 and r = 0.621 for galantamine and donepezil groups, respectively.
Frequency of Sleep Medication Use
At baseline, the mean PSQI subscore for sleep medication use during the previous week in patients was 0.17 (SE = 0.12) in the galantamine group and 0.24 (SE = 0.14) in the donepezil group. This was based on a score of 0-3 with a lower score indicating less sleep medication use. No patients in either treatment group required either new sleep medication or increased doses of sleep medication already in use throughout the 8-week study.
Global Function
The CIBIC-Plus results are presented in Figure 2 . Overall, clinicians rated all patients in the galantamine group as either improved (n = 9, 33%) or remaining unchanged (n = 18, 67%), with no patients rated as having deteriorated. In the donepezil group, clinicians rated 7 (24.1%) of the patients as improved, 18 (62.1%) as unchanged, and 4 (13.8%) as deteriorated. 
Adverse Events
Three galantamine-treated patients and four donepeziltreated patients discontinued the trial because of an AE. The most common AEs occurring over the whole trial were diarrhea (3.2% and 15.6% in the galantamine and donepezil groups, respectively), constipation (0% and 9.4%), injury (6.5% and 6.3%), pain (6.5% and 9.4%), headache (6.5% and 9.4%), nausea (9.7% and 3.1%), and bronchitis (9.7% and 0%). Most AEs were classified as mild to moderate in severity. A lower percentage of patients treated with galantamine experienced AEs during the extension phase than during the double-blind assessment phase (56.0% versus 67.7%), whereas in the donepezil group there was less of a difference (56.0% versus 53.1%). As anticipated for cholinergic agents, the incidence of AEs was highest in the gastrointestinal system.
Sleep-related AEs occurred in three patients treated with galantamine (sleep disorder characteristics; night-time wakening, increased snoring, and paroniria/nightmares each occurred in one patient), and in five patients treated with donepezil (abnormal dreaming in two patients; insomnia, somnolence, and paroniria/nightmares each in one patient). No pattern consistent with increases in sleep fragmentation or decreases in sleep quality was apparent in the Actiwatch Ò or PSQI change scores of the patients with sleep AEs.
One patient randomized to galantamine died during the trial due to congestive heart failure; however, the investigator judged this to be unrelated to study drug. Of the patients in the galantamine treatment group, three (9.7%) experienced a serious AE compared with four (12.5%) in the donepezil-treated group during the efficacy and extension phases. Only one serious AE leading to discontinuation, hepatic failure, in the donepezil-treated group was considered to be possibly due to study treatment by the investigator.
DISCUSSION
There is a paucity of data on the optimal measurement of sleep quality in AD patients, on the impact of cholinergic medications on sleep quality when used to treat AD, and the treatment of sleep disturbances in patients with AD. 22 To our knowledge, this is the first report using objective and subjective sleep measures to explore possible associations between AD treatment, changes in patient sleep, and changes in caregiver sleep.
Short-term 23 and long-term, 24 open-label, head-to-head studies of galantamine and donepezil have been reported previously. However, although this was a pilot study, it is the first double-blind, randomized, head-to-head, study of the two agents. Concerns regarding the effect of donepezil on sleep quality were raised in previous reports. [10] [11] [12] [13] [14] In this study, neither galantamine nor donepezil were associated with clinically relevant decreases in objective actigraphy measures of sleep fragmentation when patients were on stable doses of medication. However, the direction of change in these measures from baseline was consistently suggestive of improvement in the galantamine group and deterioration in the donepezil group. Actigraphy results also showed small indications of improvement in caregivers of galantamine-treated patients.
Caregivers' ratings of patients' sleep suggested that in general the patients were not experiencing sleep difficulties at baseline. Therefore, there was the potential for a floor effect. On the other hand, neither patient group showed clinically significant deterioration. When patients were divided into groups of impaired ($5) versus normal (,5) sleepers at baseline, patients with sleep impairment tended to improve in both treatment groups.
Because the caregivers reported on the patients' sleep, reports of caregivers' sleep may have mimicked those of the patient. However, caregivers of patients on galantamine reported sleep improvement after the patients' sleep improved (ie, not until patients' medication was stabilized). At this point, the sleep of caregivers of patients on galantamine tended to show some improvement, whereas the sleep of caregivers of patients on donepezil tended to slightly deteriorate. When caregivers were divided into groups of normal and impaired sleepers at trial start, the same pattern emerged. Correlations between patient and caregiver subjective PSQI measures were higher than those of the objective Actiwatch Ò measures. This may have resulted from the caregivers completing the PSQI both on themselves and on the patients.
Differences in sleep quality between galantamine and donepezil may be due to bedtime administration of donepezil, which is consistent with the product label recommendation for dosing. The longer half-life (70 hrs) of donepezil may also be a factor. 9, 14 Both galantamine and donepezil were generally safe and well tolerated in this study, with few discontinuations due to AEs and only one report of a serious AE related to study medication. Sleep-related AEs occurred infrequently, but more often in patients treated with donepezil. The sleep-related AEs reported by the patients in the donepezil group were consistent with product labeling (ie, insomnia and abnormal dreaming).
No patterns emerged in the objective and subjective sleep scores among those patients with sleep AEs. A possible explanation is that the measures used may not have been sufficiently sensitive to the emergence of these particular sleep-related AEs but rather represented a more global measure of sleep quality.
The main study limitation was the inability to draw definitive conclusions due to the small sample size as this was a pilot study. However, despite the lack of impaired sleep at baseline, this study did indicate a possible improvement in sleep with galantamine. Future studies to assess galantamine for sleep improvement should include larger sample sizes as well as patients with sleep complaints to avoid floor effects.
CONCLUSION
Results from actigraphy and PSQI data in this pilot study suggested that neither galantamine nor donepezil treatment result in clinically significant sleep disturbances in either patients or their caregivers. There were small magnitude signals on multiple measures suggesting that the sleep of galantamine-treated patients tended to improve whereas that of the donepezil group tended to decline. Both galantamine and donepezil were similarly well tolerated. The similar changes in global function suggest that the doses used, 16 mg of galantamine and 10 mg of donepezil, were appropriate for comparison.
In conclusion, the results of this pilot study are suggestive of differential effects of galantamine and donepezil on sleep, with small benefits resulting from the galantamine treatment. Additional research is needed to confirm whether these differences have any clinical significance.
